Kyle Faget, partner and member of the firm’s Health Care and Life Sciences Industry Team, was quoted in a MedTech Dive article titled, “5 Things Medtech Can Expect from FDA in 2021.”
Faget told MedTech Dive that she sees the FDA in 2021 releasing its long-awaited publication of the revised Quality System Regulation. She also stated that: “What we saw a lot of in the Trump administration was HHS getting very involved in FDA’s business and we’re going to see less of that.” She continued, “There’s going to be much more deference to FDA as an independent regulatory body.”
People
Related News
24 April 2024
In the News
Judith Waltz Discusses Nursing Home Staffing Mandate, Potential Legal Challenges
Foley & Lardner LLP partner Judith Waltz offers insight on a new nursing home staffing rule from the U.S. Department of Health and Human Services and its impact on the industry in the Bloomberg Law article, “Nursing Homes, HHS on Collision Path Over Staffing Mandate.”
23 April 2024
In the News
David Sanders Discusses Lessons Learned from General Counsel Leadership Program
Foley & Lardner LLP partner David Sanders recently joined a panel discussion with members of The Vanguard Network’s General Counsels Advisory Group to discuss the evolving role of the general counsel.
23 April 2024
In the News
Claire Marblestone Discusses HHS Final Rule on Protected Health Information Disclosure
Foley & Lardner LLP Claire Marblestone assessed the U.S. Department of Health and Human Services’ final rule that bars providers, health plans, and other entities covered by the Health Insurance Portability and Accountability Act from disclosing protected health information in a Healthcare Dive article.